Uveal Malignant Melanoma – Management Options: Proton Beam Radiotherapy

  • Anne Marie Lane
  • Ivana K. Kim
  • Evangelos S. Gragoudas
Chapter
First Online:

Abstract

Radiotherapy (RT) is the standard of care for the vast majority of malignant melanomas of the uveal tract. Eye conservation and, in many cases, maintenance of useful vision are possible.

Keywords

Optic Nerve Uveal Melanoma Proton Therapy Proton Irradiation Neovascular Glaucoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Nag S, Quivey JM, Earle JD, Followill D. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56(2):544–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Gragoudas ES, Goitein M, Koehler A, et al. Proton irradiation of choroidal melanomas: preliminary results. Arch Ophthalmol. 1978;96(9):1583–91.CrossRefGoogle Scholar
  3. 3.
    Char DH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol. 1998;125(1):81–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology. 1990;97(6):769–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003;110(11):2223–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119(7):969–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Gragoudas E, Goitein M, Seddon J, et al. Preliminary results of proton beam irradiation of macular and paramacular melanomas. Br J Ophthalmol. 1984;68(7):479–85.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Gragoudas ES, Goitein M, Verhey L, et al. Proton beam irradiation of uveal melanomas. Results of 5 1/2-year study. Arch Ophthalmol. 1982;100(6):928–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Mueller AJ, Talies S, Schaller UC, Horstmann G, Wowra B, Kampik A. Stereotactic radiosurgery of large uveal melanomas with the gamma-knife. Ophthalmology. 2000;107(7):1381–7; discussion 87–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Haas A, Pinter O, Papaefthymiou G, et al. Incidence of radiation retinopathy after high-dosage single-fraction gamma knife radiosurgery for choroidal melanoma. Ophthalmology. 2002;109(5):909–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Suit HD, Goitein M, Tepper J, et al. Exploratory study of proton radiation therapy using large field techniques and fractionated dose schedules. Cancer. 1975;35(6):1646–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Suit H. The Gray lecture 2001: coming technological advances in radiation oncology. Int J Radiat Oncol Biol Phys. 2002;53(4):798–809.PubMedCrossRefGoogle Scholar
  13. 13.
    Koehler A, Schneider R, Sisterson J. Range modulators for protons and heavy ions. Nucl Instrum Meth. 1975;131:437–40.CrossRefGoogle Scholar
  14. 14.
    Gragoudas ES. Charged particle irradiation of uveal melanoma. In: Ryan SJ, editor. Retina. 4th ed. Philadelphia: Mosby; 2006.Google Scholar
  15. 15.
    Goitein M, Miller T. Planning proton therapy of the eye. Med Phys. 1983;10(3):275–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Gragoudas ES. Charged particle irradiation of uveal melanoma. In: Ryan SJ, editor. Retina. 3rd ed. St. Louis: Mosby; 2001.Google Scholar
  17. 17.
    Gragoudas ES, Goitein M, Koehler A, et al. Proton irradiation of malignant melanoma of the ciliary body. Br J Ophthalmol. 1979;63(2):135–9.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Gragoudas E, Goitein M, Verhey L, et al. Proton beam irradiation. An alternative to enucleation for intraocular melanomas. Ophthalmology. 1980;87(6):571–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Gragoudas E, Seddon J, Egan K, et al. Long-term results of proton beam irradiated uveal melanomas. Ophthalmology. 1987;94(4):349–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118(6):773–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Egger E, Schalenbourg A, Zografos L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2001;51(1):138–47.PubMedCrossRefGoogle Scholar
  22. 22.
    Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005;62(5):1405–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Dendale R, Lumbroso-Le Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006;65(3):780–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120(12):1665–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Gragoudas E, Egan K, Seddon J, Walsh S, Munzenrider J. Intraocular recurrence of uveal melanoma after proton beam irradiation. Ophthalmology. 1992;99(5):760–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Marucci L, Lane AM, Li W, et al. Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma. Int J Radiat Oncol Biol Phys. 2006;64(4):1018–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Harbour JW, Murray TG, Byrne SF, et al. Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. Retina. 1996;16(2):129–34.PubMedCrossRefGoogle Scholar
  28. 28.
    Lane AM, Kim IK, Gragoudas ES. Proton irradiation for peripapillary and parapapillary melanomas. Arch Ophthalmol. 2011;128(9):1127–30.CrossRefGoogle Scholar
  29. 29.
    Sagoo MS, Shields CL, Mashayekhi A, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma overhanging the optic disc in 141 consecutive patients. Arch Ophthalmol. 2008;126(11):1515–22.PubMedCrossRefGoogle Scholar
  30. 30.
    Finger PT. Finger’s “slotted” eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours. Br J Ophthalmol. 2007;91(7):891–4.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Sagoo MS, Shields CL, Mashayekhi A, et al. Plaque radiotherapy for choroidal melanoma encircling the optic disc (circumpapillary choroidal melanoma). Arch Ophthalmol. 2007;125(9):1202–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Egan K, Ryan L, Gragoudas E. Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: An example of regression on time-dependent covariates. Arch Ophthalmol. 1998;116(3):366–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;55(4):867–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Fuss M, Loredo LN, Blacharski PA, Grove RI, Slater JD. Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys. 2001;49(4):1053–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Saornil M, Egan K, Gragoudas E, Seddon J, Walsh S, Albert D. Histopathology of proton beam-irradiated vs enucleated uveal melanomas. Arch Ophthalmol. 1992;110(8):1112–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Regan S, Egan KM, Hart L, Gragoudas ES. Color Doppler imaging of untreated and irradiated choroidal melanomas. Eur J Ophthalmol. 2001;11(2):150–5.PubMedGoogle Scholar
  37. 37.
    Seddon JM, Gragoudas ES, Polivogianis L, et al. Visual outcome after proton beam irradiation of uveal melanoma. Ophthalmology. 1986;93(5):666–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Seddon JM, Gragoudas ES, Egan KM, et al. Uveal melanomas near the optic disc or fovea. Visual results after proton beam irradiation. Ophthalmology. 1987;94(4):354–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology. 1999;106(8):1571–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Gragoudas ES, Lane AM. Uveal melanoma: proton beam irradiation. Ophthalmol Clin North Am. 2005;18(1):111–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Foss AJ, Whelehan I, Hungerford JL, et al. Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol. 1997;81(9):748–54.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Gragoudas ES, Egan KM, Walsh SM, Regan S, Munzenrider JE, Taratuta V. Lens changes after proton beam irradiation for uveal melanoma. Am J Ophthalmol. 1995;119(2):157–64.PubMedGoogle Scholar
  43. 43.
    Gragoudas ES. Charged particle irradiation of uveal melanoma. In: Ryan SJ, editor. Retina. 5th ed. London: Mosby; 2013.Google Scholar
  44. 44.
    Kim IK, Lane AM, Egan KM, Munzenrider J, Gragoudas ES. Natural history of radiation papillopathy after proton beam irradiation of parapapillary melanoma. Ophthalmology. 2010;117(8):1617–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Courdi A, Caujolle JP, Grange JD, et al. Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys. 1999;45(1):5–11.PubMedCrossRefGoogle Scholar
  46. 46.
    Kodjikian L, Roy P, Rouberol F, et al. Survival after proton-beam irradiation of uveal melanomas. Am J Ophthalmol. 2004;137(6):1002–10.PubMedCrossRefGoogle Scholar
  47. 47.
    Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010;128(7):871–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Gragoudas E, Egan K, Seddon J, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98(3):383–90.PubMedCrossRefGoogle Scholar
  49. 49.
    Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the MD Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76(9):1665–70.PubMedCrossRefGoogle Scholar
  50. 50.
    Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97(2):465–75.PubMedCrossRefGoogle Scholar
  51. 51.
    Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol. 1998;21(6):568–72.PubMedCrossRefGoogle Scholar
  52. 52.
    Alexander Jr HR, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9(17):6343–9.PubMedGoogle Scholar
  53. 53.
    Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res. 2004;14(3):217–22.PubMedCrossRefGoogle Scholar
  54. 54.
    Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89(7):1561–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Hsueh EC, Essner R, Foshag LJ, Ye X, Wang HJ, Morton DL. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer. 2004;100(1):122–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Shields CL, Demirci H, Marr BP, et al. Intravitreal triamcinolone acetonide for acute radiation papillopathy. Retina. 2006;26(5):537–44.PubMedCrossRefGoogle Scholar
  57. 57.
    Finger PT. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol. 2007;143(2):335–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol. 2007;125(6):751–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Lane AM, Egan KM, Harmon D, et al. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology. 2009;116(11):2206–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Anne Marie Lane
    • 1
    • 2
  • Ivana K. Kim
    • 1
    • 2
  • Evangelos S. Gragoudas
    • 1
    • 2
  1. 1.Department of OphthalmologyHarvard Medical SchoolBostonUSA
  2. 2.Retina ServiceMassachusetts Eye and Ear InfirmaryBostonUSA

Personalised recommendations